News & Updates

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

A week-long treatment course of low-dose, extended-release morphine does not appear to be effective at relieving breathlessness in patients with chronic obstructive pulmonary disease (COPD), according to a study.

Guideline-congruent screening for cervical cancer remains poor in women with systemic lupus erythematosus (SLE), according to a study.

Use of glucagon-like peptide 1 (GLP-1) receptor agonists or sodium-glucose co-transporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, helps prevent severe exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D), a UK study has shown.

Patients with moderate-to-severe systemic lupus erythematosus (SLE) appear to fare well with anifrolumab, with a recent study showing that the drug has an acceptable long-term safety profile and helps maintain reductions in disease activity and glucocorticoid usage.

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.